Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-087230
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

Zevra Therapeutics, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required |

| ☐ | Fee paid previously with preliminary materials |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

Zevra Therapeutics: All Employee Email

All,

Today, we filed our definitive proxy statement ahead of our 2025 annual meeting of stockholders. This is a standard and required filing that follows our
preliminary proxy statement, which I shared an email on a few weeks ago. The two filings are largely similar and include the same topics, including the re-election of Tamara Favorito and Wendy Dixon, Ph.D. to
our Board.

As part of this filing, we also mailed a letter to our stockholders in response to the alternative director nominees proposed by Daniel J.
Mangless. This type of letter is also commonly used when alternative directors are proposed by outside parties. Our letter is intended to encourage stockholders to vote FOR Ms. Favorito and Dr. Dixon, and refrain from voting for
Mr. Mangless’ nominees. It is also intended to remind our stockholders that our existing slate of directors have been carefully selected due to their deep expertise and diverse perspectives, and they are the candidates best positioned to
guide Zevra in its execution of its strategic plan.

Our Board and management team maintain an open dialogue with Mr. Mangless and always welcome